Rutherford-based Cancer Genetics Inc. has expanded a partnership with a Roche affiliate to improve testing at hospitals and cancer centers in Central America and the Caribbean.
The companies will work together to develop workshops and training programs to increase adoption of biomarker-based cancer diagnostics in the targeted region, according to a news release. Cancer Genetics CEO Panna Sharma said the initiative also "aligns with our focus on bringing our genomic testing to the community setting."
This agreement extends Cancer Genetics' relationship with Roche Servicios, a Costa Rica-based affiliate of Swiss pharmaceutical giant Roche.
Cancer Genetics since August 2012 has performed complex testing services for Roche Servicios to improve diagnosis and prognosis of cancer patients. The services help Roche Servicios deliver results to clinicians in 14 locations in Central America and the Caribbean.
"The workshops and training programs we are implementing will improve access to accurate genetic-based diagnostics, positively impacting therapeutic decision making in cancer care throughout the region, while adhering to the highest industry standards," said Dr. Lan Wang, a medical director at Cancer Genetics.
Roche Servicios said it will evaluate other Cancer Genetics programs that can broaden its services and range of patients serviced.
Cancer Genetics provides DNA-based cancer diagnostics test designed to personalize and improve clinical management of difficult-to-diagnose cancers. The company, which generated revenue of $4.3 million in 2012, reports that revenue has risen 54 percent year to date. Its shares went public in April.